GLP-1 & metabolic pens

Weight-Loss Peptides

Retatrutide, Cagrilintide, AOD-9604, 5-Amino-1MQ — the GLP-1 and metabolic compounds at the center of modern weight-loss research, prefilled and dose-accurate.

Compare all specs

All Weight-Loss Peptides

Low stock

5-Amino-1MQ

Dose: 100 mg
Purity: —
$ / mg: $2.79/mg

5-Amino-1MQ small-molecule NNMT-pathway inhibitor research compound — complements NAD+-salvage research. Vivaprime prefilled pen.

$310$279Crypto · save ~10%100 mg / 3 ml pen

Weight-Loss Peptides

New Low stock

Adipotide

Dose: 30 mg
Purity: —
$ / mg: $9.30/mg

Experimental pro-apoptotic peptide studied for its selective action on the vasculature supplying white adipose tissue. Prefilled in a ready-to-use pen for research use only.

$310$279Crypto · save ~10%30 mg / 3 ml pen

Weight-Loss Peptides

AOD-9604

AOD

Dose: 30 mg
Purity: —
$ / mg: $8.30/mg

Modified hGH fragment 176–191 research peptide — widely studied in adipose-tissue and lipolytic-pathway research, in a Vivaprime prefilled pen.

$280$249Crypto · save ~10%30 mg / 3 ml pen

Weight-Loss Peptides

Low stock

Cagrilintide

Cagri

Dose: 30 mg
Purity: —
$ / mg: $11.63/mg

Long-acting amylin-receptor analog studied alongside GLP-1 agonists in metabolic research. Prefilled in a ready-to-use 30 mg pen.

$390$349Crypto · save ~10%30 mg / 3 ml pen

Weight-Loss Peptides

Bestseller

Retatrutide

Reta

Dose: 30 mg
Purity: —
$ / mg: $11.63/mg

Triple GIP/GLP-1/glucagon receptor agonist research peptide — the most-anticipated next-generation metabolic compound, in a Vivaprime prefilled pen.

$390$349Crypto · save ~10%30 mg / 3 ml pen

Weight-Loss Peptides

New Low stock

Retatrutide + Follistatin Blend

Reta+FST

Dose: 30 mg
Purity: —
$ / mg: $18.30/mg

A single prefilled pen pairing the triple-agonist Retatrutide with Follistatin — formulated for research protocols focused on fat reduction while preserving lean mass. Research use only.

$610$549Crypto · save ~10%30 mg + 1.2 mg / 3 ml pen

Buyer's guide

About weight-loss peptides research peptides

Research context

This category covers incretin-axis and metabolic-pathway compounds most commonly studied in energy-balance, glycemic-control, and adipose-signaling research. All are peptide or peptide-analog agonists acting on well-characterized receptors.

Handling & stability

All GLP-1-class compounds in this category are stable refrigerated (2–8 °C) in pen format. Most retain in-use stability for 28 days after first dose — per-SKU storage notes on each product page.

Compound comparison

Semaglutide: GLP-1 mono-agonist. The most-studied compound in the class; longest-running clinical dataset.
Retatrutide: Triple agonist (GLP-1 + GIP + glucagon). Adds glucagon-receptor activity to further increase energy expenditure in preclinical models.
Cagrilintide: Long-acting amylin analog most notably co-studied with Semaglutide (the 'CagriSema' stack). Acts on amylin-receptor complexes — a different pathway from GLP-1/GIP, with additive effects on satiety signaling in published research.
AOD-9604: Non-incretin comparator. GH-fragment (hGH 176–191) studied for lipolytic effects — a distinct class from the GLP-1-axis agonists above.
5-Amino-1MQ: Small-molecule NNMT inhibitor studied in fat-cell metabolism and NAD-salvage research — a non-incretin complement to the GLP-1-axis compounds.

Every product page lists the latest COA, purity percentage, batch number, and in-use stability for that specific SKU. See also the FAQ for questions on sourcing, shipping, and research-use.

All compounds listed above are sold for in-vitro research by qualified researchers. No therapeutic, diagnostic, or consumption claim is made or implied. References to mechanisms, pathways, and studies reflect published research and are not claims about efficacy, safety, or intended use.